Compare Repligen Corporation Common Stock (RGEN) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while YieldMax TSLA Option Income Strategy ETF trades at $21.17 (market cap $675.95M). The key difference: Repligen Corporation Common Stock is far larger — about 16.5× YieldMax TSLA Option Income Strategy ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and YieldMax TSLA Option Income Strategy ETF for 45 Days on average.
| RGEN | TSLY | |
|---|---|---|
Market Cap | $11.14B | $675.95M |
Volume | 1,259,263 | 216,837 |
Sector | Health | Income / Options Overlay |
52-Week High | $194.57 | $43.35 |
52-Week Low | $102.87 | $20.49 |
Typical Hold Time | 0 Days | 45 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
TSLY trades at $22.11, down 0.58% with a bearish technical signal from moving averages. The ETF maintains consistent weekly dividend distributions averaging $0.21-0.26, though recent news highlights concerns about underperformance relative to Tesla's stock gains. Technical indicators show neutral oscillators with key support at $22 and resistance at $23.
The outlook remains cautious as TSLY faces structural challenges capturing Tesla's upside while providing income. Investors should weigh the high dividend yield against potential capital erosion during Tesla rallies. Key risks include volatility regime changes and the ETF's option strategy limitations in strong bull markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
